Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

DermTech Inc

Healthcare US DMTK

NoneUSD
0.00(0%)

Last update at 2024-09-30T06:06:54.377480Z

Day Range

--
LowHigh

52 Week Range

0.313.90
LowHigh

Fundamentals

  • Previous Close -
  • Market Cap12.24M
  • VolumeNone
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-84.68800M
  • Revenue TTM15.66M
  • Revenue Per Share TTM0.47
  • Gross Profit TTM 0.65M
  • Diluted EPS TTM-2.38

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -116.68300M -78.33500M -35.24900M -19.68900M 0.94M
Minority interest - - - - 0.00000M
Net income -113.71900M -76.97600M -34.72300M -21.90200M 0.94M
Selling general administrative 36.09M 24.84M 13.82M 8.87M 6.32M
Selling and marketing expenses 58.67M 37.58M 16.08M 6.30M -
Gross profit 0.65M 1.27M -0.09600M 0.06M -1.97803M
Reconciled depreciation 4.46M 2.30M 0.49M 0.09M -
Ebit -118.16500M -77.39800M -35.77500M -17.60500M 0.94M
Ebitda -118.30600M -76.31000M -35.28900M -17.96000M 0.94M
Depreciation and amortization -0.14100M 1.09M 0.49M -0.35500M -
Non operating income net other 0.14M -1.08800M - - 0.00000M
Operating income -118.16500M -77.39800M -35.28900M -17.60500M -1.97803M
Other operating expenses 132.68M 89.24M 41.17M 20.97M 3.96M
Interest expense 1.34M 0.15M 0.04M 2.66M 0.00000M
Tax provision - - - - -
Interest income 1.34M 0.15M - 2.66M 2.86M
Net interest income 1.34M 0.15M 0.04M -2.65700M 2.86M
Extraordinary items - - - - 0.00000M
Non recurring - - - - 0.00000M
Other items - - - - 0.00000M
Income tax expense -2.96400M -1.35900M -0.52600M 2.21M 0.00000M
Total revenue 14.52M 11.84M 5.88M 3.36M 0.00000M
Total operating expenses 118.81M 78.67M 35.19M 17.66M 1.98M
Cost of revenue 13.87M 10.56M 5.98M 3.30M 1.98M
Total other income expense net 1.48M -0.93700M 0.04M -2.08400M 2.92M
Discontinued operations - - - - 0.00000M
Net income from continuing ops -116.68300M -78.33500M -35.24900M -19.68900M 0.94M
Net income applicable to common shares -116.68300M -78.33500M -35.24900M -19.68900M -10.00400M
Preferred stock and other adjustments - - - - 0.00000M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 121.93M 202.07M 248.31M 69.78M 18.21M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 2.30M 3.94M 3.17M 1.52M 1.06M
Total liab 64.75M 69.72M 18.61M 6.29M 5.72M
Total stockholder equity 57.17M 132.35M 229.70M 63.49M 12.49M
Deferred long term liab - - - 0.64M -
Other current liab 8.68M 11.36M 6.35M 2.84M 2.72M
Common stock 0.00300M 0.00300M 0.00300M 0.00200M 0.00100M
Capital stock 0.00300M 0.00300M 0.00300M 0.00200M 0.00100M
Retained earnings -423.93500M -323.04700M -206.36400M -126.36000M -91.11100M
Other liab - 0.00500M 0.15M 0.64M -
Good will - - - - -
Other assets - 3.66M 3.19M 0.17M 0.08M
Cash 36.74M 77.76M 176.88M 24.25M 15.37M
Cash and equivalents - - - - -
Total current liabilities 13.45M 15.64M 12.18M 5.42M 5.72M
Current deferred revenue 0.20M 0.11M 1.38M 0.91M 1.39M
Net debt 17.65M -21.92600M -169.02400M -23.91300M -15.37400M
Short term debt 3.09M 1.75M 1.57M 0.11M -
Short long term debt - - - - -
Short long term debt total 54.39M 55.83M 7.86M 0.34M -
Other stockholder equity 480.93M 456.17M 436.18M 120.07M 103.60M
Property plant equipment - 6.38M 12.29M 2.73M 0.98M
Total current assets 61.75M 136.04M 232.82M 66.88M 17.15M
Long term investments - - - - -
Net tangible assets - 132.35M 229.70M 63.49M 12.49M
Short term investments 19.12M 48.41M 48.45M 39.53M 12.36M
Net receivables 2.58M 4.17M 3.85M 1.48M 0.68M
Long term debt - - - - -
Inventory 1.00M 1.76M 0.48M 0.10M 0.04M
Accounts payable 1.48M 2.42M 2.88M 1.57M 1.61M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.18M -0.77400M -0.12400M -0.00100M -0.23900M
Additional paid in capital - - - - -
Common stock total equity - 0.00300M 0.00300M 0.00200M 0.00100M
Preferred stock total equity - - - - -
Retained earnings total equity - -323.04700M -206.36400M -126.36000M -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 3.47M 3.66M 3.19M 0.17M 0.08M
Deferred long term asset charges - - - - -
Non current assets total 60.18M 66.04M 15.48M 2.90M 1.06M
Capital lease obligations 54.39M 55.83M 7.86M 0.34M -
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -1.01400M -9.79200M -39.50600M -39.50600M 136.91M
Change to liabilities 1.88M 4.33M 0.83M 1.34M -0.14500M
Total cashflows from investing activities -4.31900M -12.51200M -41.34000M -0.21000M -0.01200M
Net borrowings -0.13700M -0.17100M -0.00900M 2.08M 6.80M
Total cash from financing activities 0.92M 230.28M 78.90M 28.62M -136.88963M
Change to operating activities -2.83600M -2.78700M 1.16M -0.57800M 0.45M
Net income -116.68300M -78.33500M -35.24900M -19.68900M 0.94M
Change in cash -98.66200M 155.66M 8.87M 10.62M -0.41946M
Begin period cash flow 179.91M 24.25M 15.37M 4.75M 0.45M
End period cash flow 81.25M 179.91M 24.25M 15.37M 0.03M
Total cash from operating activities -95.26000M -62.10600M -28.68400M -17.79100M -0.44445M
Issuance of capital stock 0.00000M 158.42M 79.03M 23.80M 0.00000M
Depreciation 4.46M 2.30M 0.49M 0.09M 0.08M
Other cashflows from investing activities - - - - 136.91M
Dividends paid - - - - 0.00000M
Change to inventory -1.27700M -0.37600M -0.06900M 0.00500M 0.00800M
Change to account receivables -0.32500M -2.36700M -0.80000M -0.10000M -0.21900M
Sale purchase of stock 1.05M 230.45M 80.27M 24.74M -136.91463M
Other cashflows from financing activities 1.03M 72.03M 35.91M 9.34M 0.03M
Change to netincome 19.12M 14.38M 4.96M -0.83800M 1.26M
Capital expenditures 3.31M 2.72M 1.83M 0.21M 0.01M
Change receivables -0.32500M -2.36700M -0.80000M - 0.00000M
Cash flows other operating 1.87M 2.85M 1.99M - 0.00000M
Exchange rate changes - - - - 0.00000M
Cash and cash equivalents changes -98.66200M 155.66M 8.87M - 0.00000M
Change in working capital -2.55600M -1.19500M 1.12M 0.66M 1.53M
Stock based compensation 18.93M 13.28M 4.97M 1.30M -
Other non cash items 0.58M 1.85M -0.02100M 0.41M -2.92246M
Free cash flow -98.56500M -64.82600M -30.51800M -18.00100M -0.44445M

Peer Comparison

Sector: Healthcare Industry: Diagnostics & Research

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
DMTK
DermTech Inc		 - -% - - - 1.41 0.38 1.33 -0.2071
TMO
Thermo Fisher Scientific Inc		 -8.13 1.69% 473.95 34.71 23.87 4.62 4.43 5.29 20.89
DHR
Danaher Corporation		 1.97 1.12% 178.08 29.09 28.01 5.67 3.20 6.00 19.09
A
Agilent Technologies Inc		 2.35 1.74% 137.40 34.36 26.39 6.59 7.14 6.78 23.56
IDXX
IDEXX Laboratories Inc		 9.91 1.80% 560.73 49.99 45.66 11.29 27.85 11.46 34.46

Reports Covered

Stock Research & News

View All

Profile

DermTech, Inc., a molecular diagnostic company, engages in the development and marketing of novel non-invasive genomics tests to aid in the diagnosis and management of melanoma in the United States. The company provides DermTech Melanoma Test (DMT), an innovative non-invasive way to enhance melanoma detection for developing product for non-melanoma skin cancers. It also offers DermTech Smart Sticker, which provides a non-invasively way to collect skin sample including standard care by using scalpel to biopsy suspicious lesions. In addition, it provides research services and technology platform on a contract basis to pharmaceutical companies which use the technology for clinical trials. Further, the company develops gene expression assays for the psoriasis, atopic dermatitis, and aging of the skin to pharmaceutical companies to develop drug products in dermatology; and develop custom gene assays to support the pharmaceutical partners. It sells its products through pathology and oncology practitioners. DermTech, Inc. is headquartered in San Diego, California.

DermTech Inc

12340 El Camino Real, San Diego, CA, United States, 92130

Key Executives

Name Title Year Born
Dr. John D. Dobak M.D. Pres, CEO & Director 1966
Mr. Kevin Sun M.B.A. CFO, Treasurer & Sec. 1978
Ms. Claudia Ibarra Chief Operating Officer 1962
Mr. Ray Akhavan J.D. Gen. Counsel 1969
Mr. Todd Michael Wood Chief Commercial Officer 1969
Mr. William W. Zondler Chief Information Officer NA
Mr. Steve E. Kunszabo Sr. Director of Investor Relations NA
Ms. Jennifer Eilemberg Chief Compliance Officer NA
Mr. Ray Bassi VP of Sales NA
Dr. Burkhard Jansen M.D. Chief Medical Affairs Officer 1966

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions